Synapse

← Charles M. Perou

Papers by Charles M. Perou

Page 7 · newest first

  1. BRCA1 Suppresses Epithelial-to-Mesenchymal Transition and Stem Cell Dedifferentiation during Mammary and Tumor DevelopmentCancer Research · 2014
  2. Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor ModelsClinical Cancer Research · 2014
  3. Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older WomenThe Oncologist · 2014
  4. How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?JNCI Journal of the National Cancer Institute · 2014
  5. Predicting response and survival in chemotherapy-treated triple-negative breast cancerBritish Journal of Cancer · 2014
  6. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)Journal of Clinical Oncology · 2014
  7. Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast CancerJNCI Journal of the National Cancer Institute · 2014
  8. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusBreast Cancer Research and Treatment · 2014
  9. Integrated RNA and DNA sequencing improves mutation detection in low purity tumorsNucleic Acids Research · 2014
  10. Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian CancerClinical Cancer Research · 2014
  11. ABRA: improved coding indel detection via assembly-based realignmentBioinformatics · 2014
  12. Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profilingBMC Genomics · 2014
  13. The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II StudiesJournal of Biopharmaceutical Statistics · 2014
  14. Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor InitiationStem Cell Reports · 2014
  15. Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast CancerScience Signaling · 2014
  16. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewalJournal of Clinical Investigation · 2014
  17. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterpartsGenome biology · 2013
  18. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patternsBreast Cancer Research and Treatment · 2013
  19. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypesBreast Cancer Research and Treatment · 2013
  20. The molecular diversity of Luminal A breast tumorsBreast Cancer Research and Treatment · 2013
  21. Multiclass Distance-Weighted DiscriminationJournal of Computational and Graphical Statistics · 2013
  22. ErbB3 downregulation enhances luminal breast tumor response to antiestrogensJournal of Clinical Investigation · 2013
  23. Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsCell Reports · 2013
  24. BreakTrans: uncovering the genomic architecture of gene fusionsGenome biology · 2013
  25. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasisClinical & Experimental Metastasis · 2013
  26. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesProceedings of the National Academy of Sciences · 2013
  27. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology · 2013
  28. Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCLCancer Research · 2013
  29. Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered MiceClinical Cancer Research · 2013
  30. A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft ModelsCancer Research · 2013
  31. SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls Epithelial-Mesenchymal Transition by Inducing Wnt5a SignalingMolecular and Cellular Biology · 2013
  32. Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE SpecimensJournal of Molecular Diagnostics · 2013
  33. Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast CancerPLoS ONE · 2013
  34. Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK3CA without Affecting Mammary Tumor Latency, Gene Expression, or SignalingCancer Research · 2013
  35. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancerBreast Cancer Research and Treatment · 2013
  36. Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast CancerThe Oncologist · 2013
  37. The Genomic Landscape of Breast Cancer as a Therapeutic RoadmapCancer Discovery · 2013
  38. Integrated genomic characterization of endometrial carcinomaFaculty of Health · 2013
  39. Micro-Scale Genomic DNA Copy Number Aberrations as Another Means of Mutagenesis in Breast CancerPLoS ONE · 2012
  40. Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast CancerJournal of Clinical Oncology · 2012
  41. Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast CancerClinical Cancer Research · 2012
  42. Abstract P1-14-20: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)Cancer Research · 2012
  43. PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular MarkersBMC Medical Genomics · 2012
  44. ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing dataBMC Bioinformatics · 2012
  45. Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer SubtypesGenes & Cancer · 2012
  46. Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer ModelsClinical Cancer Research · 2012
  47. Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer DriverGenetics · 2012
  48. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancerBreast Cancer Research and Treatment · 2012
  49. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant TamoxifenClinical Cancer Research · 2012
  50. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast CancerJournal of Clinical Oncology · 2012